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provoked by gastric atrophy is the commonest cause of VBD. 
Autoimmune atrophic gastritis (AAG) is a special type of gas-
tric atrophy characterized by serum antibodies antiparietal 
cells and/or anti-intrinsic factor. AAG was an unexpected di-
agnosis since it is a relatively rare disease and the peak age of 
onset is 60 years, with only 10% of patients being <40 years of 
age. Myelopathy alone as clinical presentation is also a rare 
situation, occurring in about 12% of patients1. Concerning on 
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imagiological findings, there was not only the involvement of 
the posterior column, but also of the lateral column, rarely in-
volved in SCD4. Attention must be taken since AAG increases 
the risk of gastric carcinoid tumors and gastric carcinoma.
So, although being a rare condition, mainly in that 
age group, AAG needs to be remembered concerning its 
treatable nature and malignant potential that requires an 
appropriate follow-up.
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Fig 1. Before radiosurgery. Cranial nuclear magnetic resonance 
scan from March, 2004, revealing probable tumor residues, 
measuring 2.5 x 2.0 x 1.5 cm, with greater involvement of the 
sphenoid sinus.
Radiosurgery (RS) is a minimally invasive technique 
suitable for lesions of the central nervous system (CNS), 
with <3 cm in diameter or volume <30 mL. Benign tumors 
of the CNS are candidates to perform RS1. It has emerged as 
a therapeutic option for clinically nonfunctioning pituitary 
adenomas (CNFPA), associated with effective control of tu-
mor growth and few complications1. About 30% of pituitary 
adenomas are classified as CNFPA, and patients with this 
tumor usually have clinical symptoms, such as headaches, 
visual loss, hypopituitarism and, less commonly, pituitary 
apoplexy2. These tumors often develop slowly, but diagnosis 
tends to be late. Surgery is the primary treatment option, 
preferably transsphenoidal, complemented or not by radio-
therapy (RT) or RS1. In cases of tumor residues, the thera-
peutic approach remains controversial.
Efficacy and safety of RS in CNFPA have not been evalu-
ated as adequately as in functioning pituitary adenomas1. 
In three series of patients, with a follow-up period longer 
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Fig 2. After radiosurgery. (A) Image from June, 2004 (three months after radiosurgery); (B) image from September, 2004 (six months 
after radiosurgery), both showing growth of the sellar lesion.
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than 48 months, RS was able to control tumor growth in 93 
to 96% of the cases1-3.
Complications of RS are optic neuropathy, lesions in adja-
cent vascular structures, parenchymal brain injury, hypopitu-
itarism, and neoplasms1-4. Stenosis or occlusion of the inter-
nal carotid artery has already been reported5. 
CASE
We reported a case of a patient with CNFPA who under-
went RS and showed tumor growth after it. 
A 59-year-old male patient, single, born in São Paulo, 
Brazil, reported that a cranial computed tomography (CCT) 
performed in 1992 by headache had identified sellar and su-
prasellar tumors with 2.0 x 2.0 cm. In 2001, the CCT was re-
peated and revealed a slight increase (2.2 x 2.0 cm) of them. 
The patient denied headaches or visual loss.
Hormonal evaluation did not identify any changes. 
Nuclear magnetic resonance (NMR) scan showed sellar tu-
mor with supra- and infrasellar extension, measuring 2.2 x 
2.5 x 2.8 cm, isointense on T1 and hyperintense on T2, with 
compression of the optic chiasm. Transsphenoidal pituitary 
surgery was performed in 2001. 
The anatomicopathologic diagnosed pituitary adenoma 
with discrete anaplasia and sites reagent for thyroid-stimu-
lating hormone (TSH) in the cytoplasm.
Cranial NMR was repeated in 2001, 2002, and 2003, and 
scans revealed intrasellar content, with no signs indicating 
tumor residues. In 2004, NMR demonstrated residues with 
2.5 x 2.0 x 1.5 cm.
RS was underwent in March, 2004 (Fig 1). NMR sellar was 
underwent in June and September, 2004 (Fig 2), with lesion 
growth in six months. In January, 2005, NMR revealed a sig-
nificant reduction in tumor volume to about 1.5 cm.
A possible explanation to growth and subsequently re-
gression after RS is the occurrence of apoplexy. Reports of 
pituitary apoplexy cases after RT have promoted a relation-
ship between apoplexy and radiation1. Radiation is known 
to increase vascularization of pituitary adenomas, therefore 
leading to apoplexy.
RS is an alternative for the treatment of CNFPA, however, 
there are no reports of pituitary apoplexy or tumor growth 
after RS. A possible reabsorption of the apoplectic content 
leading to subsequent regression is likely. Tumor growth af-
ter RS, probably due to pituitary apoplexy, may be a possible 
complication of this therapeutic modality.
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